BEAM vs VRTX
BEAM and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $2.81B | $138.57B |
| P/E (TTM) | — | 35.2 |
| P/B | 2.95 | 6.63 |
| P/S | 20.2x | 11.5x |
| Revenue | $146.64M(TTM) | $12.95B(TTM) |
| Revenue growth (YoY) | 120.0% | 8.9% |
| Net income | -$108.35M(TTM) | $3.98B(TTM) |
| Earnings growth (YoY) | 78.8% | 838.1% |
| EPS, diluted | $-0.88(TTM) | $15.54(TTM) |
| EBIT margin | -274.6% | 34.8% |
| ROE | -8.4% | 18.9% |
| ROIC | -45.7% | 17.4% |
| 1y total return | +19.9% | +29.4% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: BEAM vs VRTX
| 지표 | BEAM | VRTX |
|---|---|---|
| 최종 가치 | $14.5K | $22.8K |
| 총수익률 | +44.9% | +128.5% |
| CAGR | +5.7% | +13.0% |
| 변동성 | 79.5% | 31.9% |
| 샤프 | 0.41 | 0.42 |
| 소르티노 | 0.63 | 0.57 |
| 최대 낙폭 | -89.1% | -41.6% |
공통 거래일 1696일 기준, 2020-02-06 → 2026-11-04 · 무위험수익률 4.21% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)